Actor Geoffrey Rush is seeking to suppress an amended defence by Nationwide News, arguing that if they’re made public the amendments could cause him “irreparable harm”.
A Federal Court judge has rejected a revised pleading in a class action against Ford over its allegedly defective PowerShift transmissions.
The presence of a seconded Ashurst lawyer at a Fair Work Commission hearing in an unfair dismissal case against Qantas did not violate an order denying the airline’s request to hire the firm to represent it in the case, the Fair Work Commission has found.
The administrators of collapsed startup Unlockd have withdrawn the company’s case against Google alleging the search engine giant abused its dominance to keep it out of the digital ad market.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi’s interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
Seven Network’s former director of program partnerships is suing the national broadcaster for putting her on unpaid maternity leave and extending her non-compete period after she resigned for rival Network Ten.
The first class action is expected to be filed on behalf of property owners whose buildings are covered with highly combustible polyethylene core cladding.
A month after successfully arguing for the recusal of a state Supreme Court justice from an upcoming trial over the collapse of Queensland Nickel, Clive Palmer is calling for the replacement judge to step down, alleging he too is biased against him.
Geoffrey Rush’s co-star Eryn Jean Norvill took the stand Tuesday in the actor’s defamation case against Nationwide News, telling a court she felt “panicked” and “trapped” by Rush’s allegedly inappropriate behaviour during a production of King Lear at the Sydney Theatre Company.
Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.